A self-assembling nanoparticle designed by a Univ. of Connecticut (UConn) professor is the key component of a potent new malaria vaccine that is showing promise in early tests. For years, scientists trying to develop a malaria vaccine have been stymied by the malaria parasite’s ability to transform itself and “hide” in the liver and red blood cells of an infected person to avoid detection by the immune system.
An experimental Ebola drug healed all 18 monkeys infected with the deadly virus in a study, boosting hopes that the treatment might help fight the outbreak raging through West Africa. Scientists gave the drug, called ZMapp, three to five days after infecting the monkeys in the laboratory. Most were showing symptoms by then, and all completely recovered.
A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. A semi-soft vaginal suppository made from the seaweed-derived food ingredient carrageenan and loaded with the antiviral drug Tenofovir provides a woman-initiated, drug delivery vehicle that can protect against the spread of STIs.
A fortuitous collaboration at Rice Univ. has led to the total synthesis of a recently discovered natural antibiotic. The laboratory recreation of a fungus-derived antibiotic, viridicatumtoxin B, may someday help bolster the fight against bacteria that evolve resistance to treatments in hospitals and clinics around the world.
Federal researchers next week will start testing humans with an experimental vaccine to prevent the deadly Ebola virus. The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.
Like a protective tent over a colony of harmful bacteria, biofilms make the treatment of skin infections especially difficult. Microorganisms protected in a biofilm pose a significant health risk due to their antibiotic resistance and recalcitrance to treatment, and biofilm-protected bacteria account for 80% of total bacterial infections in humans and are 50 to 1,000 times more resistant to antibiotics than simpler bacterial infections.
There’s a certain type of biomolecule built like a nano-Christmas tree. Called a glycoconjugate, it’s many branches are bedecked with sugary ornaments. It’s those ornaments that get all the glory. That’s because, according to conventional wisdom, the glycoconjugate’s lowly “tree” basically holds the sugars in place as they do the important work of reacting with other molecules.
Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases. The companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share, Roche said.
A multidisciplinary team of scientists from the Univ. of California, Los Angeles and Stanford Univ. has used a naturally occurring nanoparticle called a vault to create a novel drug delivery system that could lead to advances in the treatment of cancer and HIV. Their findings could lead to cancer treatments that are more effective with smaller doses and to therapies that could potentially eradicate the HIV virus.
As one of few Ebola survivors with medical expertise, Dr. Kent Brantly seems keenly aware of the position his painful experience has put him in. He hasn't spoken yet about his plans, but spent much of his first public appearance pleading for help for countries still struggling with the virus.
MDR-TB is a growing problem, estimated to kill 170,000 people annually and projected to infect more than two million people between 2011 and 2015. Janssen Research & Development LLC’s bedaquiline represents a significant scientific and public health advancement in the treatment of MDR-TB, as the first available medicine developed specifically for pulmonary MDR-TB treatment.
New research suggests a one-two punch could help battle polio in some of the world's most remote and strife-torn regions: Giving a single vaccine shot to children who've already swallowed drops of an oral polio vaccine greatly boosted their immunity. The World Health Organization officials said the combination strategy already is starting to be used in mass vaccination campaigns in some hard-hit areas.
Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease. The Indianapolis-based company announced initial results from the research on Thursday and said it plans to submit the drug, ixekizumab, to regulators in the first half of next year.
As anyone who has bitten into a chili pepper knows, its burning spiciness—though irresistible to some—is intolerable to others. Scientists exploring the chili pepper’s effect are using their findings to develop a new drug candidate for many kinds of pain, which can be caused by inflammation or other problems. They reported their progress on the compound, which is being tested in clinical trials, in the Journal of Medicinal Chemistry.
Texas researchers are reporting that an experimental drug saved monkeys from a virus closely related to Ebola even after symptoms began. The drug targets a strain of Marburg virus that is even more lethal than the Ebola currently ravaging West Africa. Both viruses take time to multiply in the body before symptoms appear, and few studies have explored how late treatment might be effective.
Two Northwestern Univ. scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.
British drugmaker AstraZeneca says the U.S. Dept. of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The company announced in October 2013 that federal officials were looking into the 18,000-patient study, which began in 2009.
Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines, but it won't be easy to prove that the shots and other potential treatments in the pipeline really work. There are no proven drugs or vaccines for Ebola, a disease so rare that it's been hard to attract investments in countermeasures. But the current outbreak in West Africa is fueling new efforts to speed Ebola vaccine and drug development.
A new technique has demonstrated for the first time that the size of molecules penetrating the blood-brain barrier can be controlled using acoustic pressure. The innovative ultrasound approach uses acoustic pressure to let molecules through, and may help treatment for central nervous system diseases like Parkinson’s and Alzheimer’s.
By combining magnetic nanoparticles with one of the most common and effective chemotherapy drugs, Argonne National Laboratory researchers have created a way to deliver anti-cancer drugs directly into the nucleus of cancer cells. They have created nano-sized bubbles, or “micelles,” that contain magnetic nanoparticles of iron oxide and cisplatin, a conventional chemotherapy drug also known as “the penicillin of cancer.”
A federal panel says older Americans should start getting a new vaccine against bacteria that cause pneumonia. The Advisory Committee on Immunization Practices voted Wednesday to recommend a dose of the expensive new shot for people 65 and older. The panel said older adults should still get an older pneumococcal vaccine, too.
Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists’ efforts to study its genetics. It can take up to a year to determine the function of a single gene, which has slowed efforts to develop new, more targeted drugs and vaccines. Biological engineers have now demonstrated a new genome-editing technique that can disrupt a single parasite gene in a matter of weeks.
Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer’s disease in an animal model. The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory. These cognitive functions are impaired in Alzheimer’s.
The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. But some health experts fear debate over extremely limited doses will distract from tried-and-true measures to curb the growing outbreak.
A new technique for studying the lifecycle of the hepatitis B virus could help researchers develop a cure for the disease. A recently published paper describes using microfabricated cell cultures to sustain hepatitis B virus in human liver cells, allowing them to study immune responses and drug treatments.